Works matching IS 01676997 AND DT 2023 AND VI 41 AND IP 1

Results: 21

A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 162, doi. 10.1007/s10637-023-01335-w

By:

Zhou, Mingzhen;
Zhu, Sihui;
Xu, Chen;
Liu, Baorui;
Shen, Jie

Publication type:

Article

Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 153, doi. 10.1007/s10637-023-01333-y

By:

Vedenkin, Alexander S.;
Stovbun, Sergey V.;
Bukhvostov, Alexander A;
Zlenko, Dmitry V.;
Stovbun, Ivan S.;
Silnikov, Vladimir N.;
Fursov, Valentin V.;
Kuznetsov, Dmitry A.

Publication type:

Article

Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 142, doi. 10.1007/s10637-023-01332-z

By:

Scherbakov, Alexander M.;
Vorontsova, Svetlana K.;
Khamidullina, Alvina I;
Mrdjanovic, Jasminka;
Andreeva, Olga E.;
Bogdanov, Fedor B.;
Salnikova, Diana I.;
Jurisic, Vladimir;
Zavarzin, Igor V.;
Shirinian, Valerii Z.

Publication type:

Article

Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 134, doi. 10.1007/s10637-023-01330-1

By:

Yan, Gaobo;
Zhang, Hongyan;
Li, Yan;
Miao, Guoqiang;
Liu, Xiaolei;
Lv, Qifan

Publication type:

Article

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 122, doi. 10.1007/s10637-023-01328-9

By:

Ishikawa, Emi;
Yokoyama, Yuta;
Chishima, Haruna;
Kasai, Hidefumi;
Kuniyoshi, Ouki;
Kimura, Motonori;
Hakamata, Jun;
Nakada, Hideo;
Suehiro, Naoya;
Nakaya, Naoki;
Nakajima, Hideo;
Ikemura, Shinnosuke;
Kawada, Ichiro;
Yasuda, Hiroyuki;
Terai, Hideki;
Jibiki, Aya;
Kawazoe, Hitoshi;
Soejima, Kenzo;
Muramatsu, Hiroshi;
Suzuki, Sayo

Publication type:

Article

Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 115, doi. 10.1007/s10637-023-01327-w

By:

Manaka, Hiroya;
Igawa, Satoshi;
Yamamoto, Michiko;
Oguri, Akito;
Manabe, Hideaki;
Kasajima, Masashi;
Kusuhara, Seiichiro;
Hosotani, Shinji;
Nakahara, Yoshiro;
Sato, Takashi;
Fukui, Tomoya;
Hisashi, Mitsufuji;
Sasaki, Jiichiro;
Naoki, Katsuhiko

Publication type:

Article

Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 86, doi. 10.1007/s10637-022-01324-5

By:

Hou, Helei;
Wang, Yongjie;
Sun, Dantong;
Zhu, Jingjuan;
Jiang, Man;
Zhang, Xuchen;
Zhou, Na;
Zhang, Chuantao;
Li, Tianjun;
Zhang, Xiaochun

Publication type:

Article

Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma.

Published in:

2023

By:

Yuan, Peng;
Song, Jinhua;
Wang, Fei;
Zhu, Guangyu;
Chen, Baoan

Publication type:

Correction Notice

A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 76, doi. 10.1007/s10637-022-01322-7

By:

Takahara, Naminatsu;
Nakai, Yousuke;
Isayama, Hiroyuki;
Sasaki, Takashi;
Morine, Yuji;
Watanabe, Kazuo;
Ueno, Makoto;
Ioka, Tatsuya;
Kanai, Masashi;
Kondo, Shunsuke;
Okano, Naohiro;
Koike, Kazuhiko

Publication type:

Article

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 173, doi. 10.1007/s10637-022-01321-8

By:

Takamizawa, Shigemasa;
Katsuya, Yuki;
Chen, Yi-Ning;
Mizuno, Takaaki;
Koyama, Takafumi;
Sudo, Kazuki;
Yoshida, Tatsuya;
Kondo, Shunsuke;
Iwasa, Satoru;
Yonemori, Kan;
Shimizu, Toshio;
Yamamoto, Noboru;
Suzuki, Shigenobu

Publication type:

Article

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 93, doi. 10.1007/s10637-022-01319-2

By:

Moreno, Victor;
Perets, Ruth;
Peretz-Yablonski, Tamar;
Fourneau, Nele;
Girgis, Suzette;
Guo, Yue;
Hellemans, Peter;
Verona, Raluca;
Pendás, Natalia;
Xia, Qi;
Geva, Ravit;
Calvo, Emiliano

Publication type:

Article

Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 60, doi. 10.1007/s10637-022-01320-9

By:

Liu, Zhengzhi;
Xu, Zhongnan;
Gao, Zhenyue;
Ren, Qing;
Chang, Tianying;
Xue, Jinling;
Yang, Haimiao

Publication type:

Article

A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 53, doi. 10.1007/s10637-022-01318-3

By:

Steeghs, Neeltje;
Pruis, Melinda;
van Herpen, Carla;
Lu, Vickie;
Redman, John;
Zhou, Xiaofei

Publication type:

Article

An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 70, doi. 10.1007/s10637-022-01317-4

By:

Vijayakumar, Jayanthi;
Haddad, Tufia;
Gupta, Kalpna;
Sauers, Janet;
Yee, Douglas

Publication type:

Article

Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 44, doi. 10.1007/s10637-022-01316-5

By:

Qian, Kun;
Chen, Qi-Rui;
He, Ming;
Wang, Zi-Tong;
Liu, Yu;
Liang, Hua-Gang;
Su, Zhi-Yong;
Cui, Yu-Shang;
Liu, Li-Jun;
Zhang, Yi

Publication type:

Article

The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 13, doi. 10.1007/s10637-022-01314-7

By:

Qi, Defei;
Dou, Yuanyuan;
Zhang, Wenke;
Wang, Mengqing;
Li, Yingying;
Zhang, Mingzhu;
Qin, Jia;
Cao, Jinlan;
Fang, Dong;
Ma, Jing;
Yang, Wei;
Xie, Songqiang;
Sun, Hua

Publication type:

Article

Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 168, doi. 10.1007/s10637-022-01312-9

By:

Kinoshita, Fumihiko;
Oku, Yuka;
Takamori, Shinkichi;
Fujishita, Takatoshi;
Toyozawa, Ryo;
Ito, Kensaku;
Shoji, Fumihiro;
Okamoto, Tatsuro

Publication type:

Article

Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 35, doi. 10.1007/s10637-022-01309-4

By:

Shima, Yusuke;
Sato, Yuki;
Morimoto, Takeshi;
Hara, Shigeo;
Hirabayashi, Ryosuke;
Nagata, Kazuma;
Nakagawa, Atsushi;
Tachikawa, Ryo;
Hamakawa, Hiroshi;
Takahashi, Yutaka;
Tomii, Keisuke

Publication type:

Article

Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 25, doi. 10.1007/s10637-022-01308-5

By:

Pant, Shubham;
Dragovich, Tomislav;
Lieu, Christopher;
Jimeno, Antonio;
Kundranda, Madappa;
Menter, David;
Tchaparian, Eskouhie;
Chen, Yuchih C.;
Kopetz, Scott

Publication type:

Article

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 1, doi. 10.1007/s10637-022-01307-6

By:

Shimizu, Toshio;
Nakagawa, Kazuhiko;
Hayashi, Hidetoshi;
Iwasa, Tsutomu;
Kawakami, Hisato;
Watanabe, Satomi;
Yamamoto, Noboru;
Yonemori, Kan;
Koyama, Takafumi;
Sato, Jun;
Tamura, Kenji;
Kikuchi, Keiichi;
Akaike, Kenichiro;
Takeda, Shiho;
Takeda, Masayuki

Publication type:

Article

DGG-300273, a novel WNT/β-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 105, doi. 10.1007/s10637-022-01295-7

By:

Kim, Do Yeon;
Ryu, Yea Seong;
Lee, Eun-Sil;
Koh, Dong-In;
Moon, Jai-Hee;
Jung, Soo-A;
Kim, Mi Jin;
Yun, Hyeseon;
You, Ji-Eun;
Jeong, Hong-Rae;
Yoon, Dong-Il;
Kim, Chul Hee;
Hong, Seung-Woo;
Gong, Young-Dae;
Jin, Dong-Hoon

Publication type:

Article